USPTO trademark

SINGULERA

Under examinationUSPTOFigurative markClass 5Class 40Class 42Class 44

"SINGULERA" is a figurative mark owned by Singulera Therapeutics Inc., filed at the USPTO on October 5, 2026. It is under examination and covers classes 5, 40, 42 and 44.

Get this data via the API
Official USPTO record
SINGULERA trademark as filed
As filed with the USPTO
Status
Under examination
Since October 5, 2026
Filed
October 5, 2026
Registered
Not yet
Priority date
September 24, 2026
Claimed from Taiwan
Application no.
50145475
Registration no.
Not yet
Office
USPTO
United States Patent and Trademark Office
Mark type
Figurative mark
4 classes
Ownership

Who owns SINGULERA

The owner and representative on file with the office.

Owner

Singulera Therapeutics Inc.

Chicago, United States

Representative

Angel Roman Campos

Goods and services

What the mark covers

The products and services SINGULERA is filed for, grouped by Nice class.

  • Syringes sold filled with pharmaceuticals for the treatment of osteoarthritis and other degenerative joint diseases; Syringes sold filled with pharmaceuticals for chronic wound healing, including non-healing ulcers; Syringes sold filled with immune-modulating pharmaceuticals for autoimmune diseases and transplant rejection prevention; Syringes sold filled with pharmaceuticals for cardiovascular diseases, including acute myocardial infarction and ischemic conditions; Syringes sold filled with regenerative pharmaceuticals for skin and tissue repair; Organotherapy preparations; Biological preparations for use in cell cultures for medical purposes; Pharmaceutical and biological preparations for diagnostic, medical, therapeutic and prophylactic use, namely for the treatment of genetic, autoimmune and inflammatory diseases, disorders and deficiencies, and for preventing organ transplant rejection; Pharmaceutical preparations for use in treatment, amelioration and prophylaxis of diseases, disorders and suppression of the immune system; Pharmaceutical preparations for cell therapy for medical purposes; Pharmaceutical preparations for gene therapy for medical purposes; Pharmaceutical preparations for genetically modifying human and animal cells for diagnostic and medical purposes; Pharmaceutical preparations for therapies to modulate the immune system; Pharmaceutical preparations for therapeutic delivery of nucleic acids; Medical pharmaceutical preparations containing viral vectors for therapeutic and prophylactic purposes for the treatment of genetic, autoimmune and inflammatory diseases, disorders and deficiencies, and for preventing organ transplant rejection; Medical preparations containing nucleic acid vectors for therapeutic and prophylactic purposes for the treatment of genetic, autoimmune and inflammatory diseases, disorders and deficiencies, and for preventing organ transplant rejection; Stem cells for medical purposes; Opotherapy preparations; Biological reagent for medical purposes; Immunostimulants

  • Custom manufacturing of pharmaceuticals; Custom manufacturing of biological tissue, blood, cell and genetic material; Custom manufacturing of biological preparations; Custom biomanufacturing of pharmaceutical preparations; Custom biomanufacturing of pharmaceuticals containing cultured cells for use in cell therapy; Custom manufacturing of cell therapy preparations; Contract biomanufacturing in the field of pharmaceuticals

  • Biological research; Biotechnological research; Medical research; Research and development of new products for others; Technological research in the field of biotechnology; Conducting technical project studies; Industrial research in the field of biotechnology; Research and development of pharmaceutical preparations; Conducting clinical trials for others; Research and development in the field of cell therapy; Research and development in the field of biopharmaceuticals; Research and development of pharmaceutical manufacturing processes; Research and development of biopharmaceutical manufacturing processes; Testing and analysis of pharmaceutical products

  • Medical services; Medical and pharmaceutical consultation; Providing medical information; Stem cell therapy services; Immunotherapy services; Medical treatment services for autoimmune diseases; Medical services for the prevention and treatment of organ transplant rejection

History

What has happened so far

Steps recorded by the USPTO, newest first.

  1. Application filing receipt mailed
  2. New application entered
FAQ

About SINGULERA

Who owns the trademark "SINGULERA"?

The USPTO trademark "SINGULERA" (application 50145475) is owned by Singulera Therapeutics Inc.

What is the status of "SINGULERA"?

Its status at the USPTO is: under examination.

API

Get this data via the API

Everything on this page comes from the Signa API. Pull SINGULERA and marks like it into your own product with one request.

  • GET/v1/trademarks/{id}

    The full record: owners, classes, dates and images

  • GET/v1/trademarks/{id}/events

    Every step in the office history

  • GET/v1/proceedings?trademark_id={id}

    Oppositions and cancellations against the mark

Get API keyView docs
GET /v1/trademarks/{id}
ID=tm_01a1115a-dc16-72bf-8ee8-ab8c7f437c54
curl https://api.signa.so/v1/trademarks/$ID \
  -H "Authorization: Bearer $SIGNA_API_KEY"
Response
{
  "id": "tm_01a1115a-dc16-72bf-8ee8-ab8c7f437c54",
  "object": "trademark",
  "mark_text": "SINGULERA",
  "status": {
    "primary": "pending",
    "stage": "examining"
  },
  "office_code": "US",
  "application_number": "50145475",
  "filing_date": "2026-10-05",
  "nice_classes": [
    5,
    40,
    42,
    44
  ],
  "owners": [
    {
      "name": "Singulera Therapeutics Inc.",
      "entity_id": null
    }
  ]
}